1
|
Bhattacharya S, Sharma S, Prajapati BG. Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN. Front Oncol 2022; 12:990841. [DOI: 10.3389/fonc.2022.990841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Accepted: 10/07/2022] [Indexed: 11/13/2022] Open
Abstract
The study aimed to create D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) nanostructured lipid carriers (NLC) of sorafenib tosylate (ST) as lymphatic delivery systems (LDDS) to fight Metastatic colorectal cancer. Initially, ST-SLN, ST-NLC, and ST-LNE were formulated considering oleic acid (OA), glycerol monolinoleate (GMO), glycerol monolinoleate (GML) as solid lipid and further characterised, and tested for stability. The most stable ST-NLC was fabricated with TPGS to produce ST-TPGS-NLC and evaluated by performing in vitro drug profiling, in vitro cytotoxicity, and apoptotic studies against human female colorectal adenocarcinoma cell lines (SW48 Cells PTEN). Stability studies on three lipidic nanoparticles (ST-SLN, ST-NLC, ST-LEN) showed particle size, polydispersity index, and zeta potential ranging from 165 nm to 298 nm, 0.125 to 0.288, and -31 mV to -16 mV. At 1600 minutes, more than 80% of ST-NLC1 was released, confirming the sustained release pattern of the formulation. ST-NLC and ST-TPGS-NLC have entrapment efficiencies above 50%. Pure ST’s IC50 at 72 hr was 3.45 µg/mL, while 1.56 µg/mL was for ST-TPGS-NLC. The ST-TPGS-NLC reduced the number of livings SW48 Cells PTEN from 91% to 5%, compared to 75% to 8% of pure ST. The ST-TPGS-NLC is a promising LDDS for delivering ST for metastatic colorectal cancer.
Collapse
|
2
|
Sora S, Sukhbaatar A, Fukushige S, Mori S, Sakamoto M, Kodama T. Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model. Cancer Sci 2022; 114:227-235. [PMID: 36056924 PMCID: PMC9807513 DOI: 10.1111/cas.15562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 08/22/2022] [Accepted: 08/24/2022] [Indexed: 01/07/2023] Open
Abstract
Chemotherapy using a lymphatic drug delivery system (LDDS) targeting lymph nodes (LNs) in the early stage of metastasis has a superior antitumor effect to systemic chemotherapy. An LDDS produces a higher drug retention rate and tissue selectivity in LNs. To expand the therapeutic coverage of LDDS from local treatment of metastatic LNs to prevention of distant metastases, the combination of treatment with therapies that enhance systemic tumor immune effects is an important therapeutic strategy. Recently, total body irradiation (TBI) has been shown to activate immune responses and alter the tumor microenvironment. Here we show that combination therapy with TBI and LDDS improves the antitumor effect of metastatic LNs and lung metastasis. Tumor cells were inoculated into the subiliac LN (SiLN) to induce metastasis into the proper axillary LN (PALN) and lung in a mouse model. TBI was carried out on day 4 after inoculation using a gamma irradiator. Lymphatic drug delivery into the accessory axillary LN was used to treat PALN. In vivo bioluminescence imaging, high-frequency ultrasound, and histology showed that combination therapy using TBI (total dose 1.0 Gy once) and the LDDS suppressed tumor growth in LNs and lung metastases and was more effective than using LDDS or TBI alone. Quantitative RT-PCR of spleens after combination therapy revealed increased expression of CD4, CD8, and IL-12b, indicating an activated immune response. The results show that combination therapy with TBI and LDDS is a method to improve the efficacy of LN metastases and distant metastases therapy and is a promising novel approach to treat cancer patients.
Collapse
Affiliation(s)
- Shota Sora
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan
| | - Ariunbuyan Sukhbaatar
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan,Biomedical Engineering Cancer Research Center, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan
| | - Shinichi Fukushige
- Department of Metabolism and Diabetes, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Shiro Mori
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan,Biomedical Engineering Cancer Research Center, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan
| | - Maya Sakamoto
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan,Biomedical Engineering Cancer Research Center, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan
| | - Tetsuya Kodama
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan,Biomedical Engineering Cancer Research Center, Graduate School of Biomedical EngineeringTohoku UniversitySendaiJapan
| |
Collapse
|
3
|
Oladipo AO, Lebepe TC, Ncapayi V, Tsolekile N, Parani S, Songca SP, Mori S, Kodama T, Oluwafemi OS. The Therapeutic Effect of Second Near-Infrared Absorbing Gold Nanorods on Metastatic Lymph Nodes via Lymphatic Delivery System. Pharmaceutics 2021; 13:pharmaceutics13091359. [PMID: 34575435 PMCID: PMC8466320 DOI: 10.3390/pharmaceutics13091359] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 08/06/2021] [Accepted: 08/10/2021] [Indexed: 11/17/2022] Open
Abstract
Photothermal therapy has been established recently as a non-invasive treatment protocol for cancer metastatic lymph nodes. Although this treatment approach shows efficient tumour ablation towards lymph node metastasis, the monitoring and reporting of treatment progress using the lymphatic delivery channel still need to be explored. Herein, we investigated the anti-tumour effect of pegylated gold nanorods with a high aspect ratio (PAuNRs) delivered via the lymphatic route in a mouse model. In this study, breast carcinoma (FM3A-Luc) cells were inoculated in the subiliac lymph node (SiLN) to induce metastasis in the proper axillary lymph node (PALN). The treatment was initiated by injecting the PAuNRs into the accessory axillary lymph node (AALN) after tumour metastasis was confirmed in the PALN followed by external NIR laser irradiation under a temperature-controlled cooling system. The anti-tumour impact of the treatment was evaluated using an in vivo bioluminescence imaging system (IVIS). The results showed a time-dependent reduction in tumour activity with significant treatment response. Tumour growth was inhibited in all mice treated with PAuNRs under laser irradiation; results were statistically significant (** p < 0.01) even after treatment was concluded on day 3. We believe that this non-invasive technique would provide more information on the dynamics of tumour therapy using the lymphatically administered route in preclinical studies.
Collapse
Affiliation(s)
- Adewale O. Oladipo
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
| | - Thabang C. Lebepe
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
| | - Vuyelwa Ncapayi
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
| | - Ncediwe Tsolekile
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
| | - Sundararajan Parani
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
| | - Sandile P. Songca
- Department of Chemistry, University of KwaZulu-Natal, Private Bag X 54001, Durban 4000, South Africa;
| | - Shiro Mori
- Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai 980-8575, Japan;
- Department of Oral and Maxillofacial Surgery, Tohoku University Hospital, 1-1 Seiryo, Aoba, Sendai 980-8575, Japan
| | - Tetsuya Kodama
- Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai 980-8575, Japan;
- Correspondence: (T.K.); (O.S.O.)
| | - Oluwatobi S. Oluwafemi
- Department of Chemical Sciences, University of Johannesburg Doornfontein Campus, Johannesburg 2028, South Africa; (A.O.O.); (T.C.L.); (V.N.); (N.T.); (S.P.)
- Centre for Nanomaterials Science Research, University of Johannesburg, Johannesburg 2028, South Africa
- Correspondence: (T.K.); (O.S.O.)
| |
Collapse
|